Lok Sabha: Oppn members seek to know govt's stand on Covid booster dose

TMC and NCP members on Thursday sought information from government on booster doses

Parliament
Press Trust of India New Delhi
2 min read Last Updated : Dec 03 2021 | 2:39 AM IST

Members of opposition TMC and NCP on Thursday sought to know from the government its stand on booster doses for COVID-19, besides usage of money from the PM-CARES funds.

Participating in a discussion on the COVID-19 pandemic in Lok Sabha, TMC member Saugata Roy accused the political leadership of "complacency" in handling of the pandemic.

He said it is because of the "mistakes" at the top level of the government that the country was caught "unprepared" in both the waves of COVID-19.

"Till today, I do not know about what happened to other vaccines that have been discovered in the world -- Pfizer, Moderna, Johnson & Johnson. Whether all these vaccines have come to India and whether they can be used?" he said.

Is a booster dose necessary, Roy asked and added that the Indian Council of Medical Research (ICMR) has not issued any directive yet.

NCP's Supriya Sule said states have also contributed to the PM-CARES fund, and sought to know how the Centre is distributing the money to states.

"What is your stand on the third dose? We all have ageing parents, families, health workers ... they all are anxious because there is no clarity," she said, asking the government to also make it clear that booster and third dose are the same.

Ritesh Pandey (BSP) accused the government of "leadership failure" in handling the pandemic and said in India less than one per cent of RT-PCR tests are sent for genome sequencing, which is the lowest among G-20 countries.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusParliamentCoronavirus Vaccine

First Published: Dec 03 2021 | 2:39 AM IST

Next Story